Ex-Re­cep­tos CTO co-founds SD start­up Escient, launch­ing with $40M Se­ries A

Af­ter the whop­ping $7.2 bil­lion sale of his last ven­ture, Re­cep­tos, to Cel­gene back in 2015, Mar­cus Boehm wasn’t sup­posed to start an­oth­er com­pa­ny. He was go­ing to take a back­seat, for once. Con­sult. Be on a few boards.

“I’ve been in­volved in three com­pa­nies since found­ing stages, and I was not in­tend­ing to do this again,” Boehm tells me.

Now, he and an­oth­er biotech big shot in San Diego are join­ing forces to launch a rather am­bi­tious start­up, step­ping out Wednes­day with a $40 mil­lion Se­ries A round.

Mar­cus Boehm

You might know Boehm’s name from his time at San Diego’s Re­cep­tos, where he was co-founder and chief tech­nol­o­gy of­fi­cer un­til Cel­gene’s pur­chase. Be­fore that, he was at Con­for­ma un­til it was bought by Bio­gen. Af­ter Re­cep­tos’ sale, Boehm had in­ten­tions of kick­ing back for a while.

But then Alain Baron came along, and he in­tro­duced Boehm to dis­cov­er­ies made by Johns Hop­kins neu­ro­sci­en­tist Xinzhong Dong. To­geth­er, the three of them co-found­ed Escient Phar­ma­ceu­ti­cals, a new San Diego-based com­pa­ny that plans to cre­ate an en­tire­ly new class of drugs.

Boehm said it was this — the al­lure of dis­cov­ery-stage sci­ence — that drew him back in­to the start­up game. If it was a com­pa­ny fur­ther along in de­vel­op­ment, he’d have like­ly passed.

“In many ways, a com­pound will live or die by its prop­er­ties,” Boehm said. “Once it’s in Phase II, there’s not much you can af­fect. If it has tox­i­c­i­ty, for ex­am­ple, there’s not much you can do about it. The dis­cov­ery part is over, and it be­comes a high­ly-or­ches­trat­ed dance of de­vel­op­ment.”

Alain Baron

Boehm serves as Escient’s CSO, while Baron, the founder and for­mer chief ex­ec­u­tive of El­celyx, will head the start­up as CEO.

The com­pa­ny hopes to de­vel­op a pipeline of drugs around a nov­el fam­i­ly of G-pro­tein cou­pled re­cep­tors (GPCRs). GPCRs them­selves are a gi­ant pro­tein fam­i­ly of re­cep­tors that de­tect mol­e­cules out­side the cell and ac­ti­vate cel­lu­lar re­spons­es. If you had to make a wild guess about the tar­get of a cer­tain drug, your best bet is with GPCRs. They make up some­thing like 35% of all drugs on the mar­ket to­day, Baron said.

But Escient has its hands on tech from Dong’s lab on a nov­el fam­i­ly of Mas-re­lat­ed G-pro­tein re­cep­tors, which Baron said have the po­ten­tial to be a com­plete­ly new class of GCPR-tar­get­ed drugs.

“This is not like tak­ing a known tar­get and mak­ing a bet­ter drug or bring­ing an­oth­er med­i­cine to a dis­ease area that’s al­ready well-served,” Baron said. “We’re ac­tu­al­ly go­ing to bring very nov­el ther­a­pies to dis­eases that are un­served — and that’s in­cred­i­bly ex­cit­ing.”

Xinzhong Dong

Baron and Boehme aren’t dis­clos­ing much on their tech, but they did say Escient has nailed down two tar­gets in two in­di­ca­tions. The Se­ries A round — backed by The Col­umn Group, 5AM Ven­tures, and Os­age Uni­ver­si­ty Part­ners — will get the com­pa­ny to the end of 2021. Baron ex­pects the com­pa­ny to be in the clin­ic with one or two pro­grams by then.

In the com­ing months, Escient will be nail­ing down of­fice space for its head­quar­ters in San Diego, hir­ing 15 to 20 peo­ple, and fill­ing out their ex­ec­u­tive team, Baron said.

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

AJ Patel was recovering from a complicated brain surgery when his oncologist burst into the hospital room yelling, “I’ve got some really great news for you!”

For two years, Patel had been going from doctor to doctor trying to diagnose his wheezing, only to be dealt the devastating news that he had stage IV lung cancer and only six months to live. And then they found the brain tumors.

“What are you talking about?” Patel asked. He had never seen an oncologist so happy.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Mihael Polymeropoulos, Vanda Pharmaceuticals CEO

Phar­ma com­pa­ny con­tin­ues its FDA law­suit spree, this time af­ter agency de­nies fast-track des­ig­na­tion

Vanda Pharmaceuticals is making a name for itself, at least in terms of suing the FDA.

The DC-headquartered firm on Monday filed its latest suit against the agency, with the company raising concerns over the FDA’s failure to grant a fast track designation for Vanda’s potential chronic digestive disorder drug tradipitant, which is a neurokinin 1 receptor antagonist.

Specifically, Vanda said FDA’s “essential point” in its one-page denial letter on the designation pointed to “the lack of necessary safety data,” which was “inconsistent with the criteria for … Fast Track designation.”

Mod­er­na seeks to dis­miss Al­ny­lam suit over Covid-19 vac­cine com­po­nent, claim­ing wrong venue

RNAi therapeutics juggernaut Alnylam Pharmaceuticals made a splash in March when it sued and sought money from both Pfizer and Moderna regarding their use of Alnylam’s biodegradable lipids, which Alnylam claims have been integral to the way both companies’ mRNA-based Covid-19 vaccines work.

But now, Moderna lawyers are firing back, telling the same Delaware district court that Alnylam’s claims can only proceed against the US government in the Court of Federal Claims because of the way the company’s contract is set up with the US government. The US has spent almost $10 billion on Moderna’s Covid-19 vaccine so far.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

(Credit: Shutterstock)

Cracks in the fa­cade: Is phar­ma's pan­dem­ic ‘feel good fac­tor’ wan­ing?

The discordant effects of the Covid-19 pandemic on pharma reputation continues. While the overall industry still retains a respectable halo from its Covid-19 quick response and leadership, a new patient group study reveals a different story emerging in the details.

On one hand, US patient advocacy groups rated the industry higher-than-ever overall. More than two-thirds (67%) of groups gave the industry a thumbs up for 2021, a whopping 10 percentage point increase over the year before, according to the PatientView annual study, now in its 9th year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Alan Wise (L) and Peter Trill (Duke Street Bio)

They sold their last biotech to Mer­ck. Now they're back with a PARP out­fit named af­ter a Lon­don street

In 2016, Peter Trill and Alan Wise sold IOmet Pharma (an I/O outfit as the name suggests) to Merck for $400 million.

Now, some six years later, the duo has returned with another cancer biotech, Duke Street Bio, that emerged from stealth Tuesday. Duke Street Bio, named for the street where it’s located in London, is making its public debut as a next-gen PARP player, hoping to break into a field that already has a number of Big Pharma competitors.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Michael Corbo, Pfizer CDO of inflammation & immunology

UP­DAT­ED: Plan­ning ahead for crowd­ed ul­cer­a­tive col­i­tis mar­ket, Pfiz­er spells out PhI­II da­ta on $6.7B Are­na drug

Pfizer has laid out the detailed results behind its boast that etrasimod — the S1P receptor modulator at the center of its $6.7 billion buyout of Arena Pharma — is the winner of the class, potentially leapfrogging an earlier entrant from Bristol Myers Squibb.

Pivotal data from the ELEVATE program in ulcerative colitis — which consists of two Phase III trials, one lasting 52 weeks and the other just 12 weeks — illustrate an “encouraging balance of efficacy and safety,” according to Michael Corbo, chief development officer of inflammation & immunology at Pfizer. The company is presenting the results as a late breaker at Digestive Disease Week.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Robert Califf (Michael Brochstein/Sipa USA via AP Images)

House Re­pub­li­cans at­tack Chi­na-on­ly da­ta in FDA sub­mis­sions, seek new in­ves­ti­ga­tion in­to re­search in­spec­tions

Three Republican representatives are calling on the FDA to take a closer look at the applications including only clinical data from China.

The letter to FDA commissioner Rob Califf late last week comes as the agency recently rejected Eli Lilly’s anti-PD-1 antibody, which attempted to bring China-only data but ran into a bruising adcomm that may crush the hopes of any other companies looking to bring cheaper follow-ons based only on Chinese data.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Amid mon­key­pox fears, biotechs spring to ac­tion; Mod­er­na’s CFO trou­ble; Cuts, cuts every­where; Craft­ing the right pro­teins; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

It’s always a bittersweet moment saying goodbye, but as Josh Sullivan goes off to new adventures we are grateful for the way he’s built up the Endpoints Manufacturing section — which the rest of the team will now carry forward. If you’re not already, this may be a good time to sign up for your weekly dose of drug manufacturing news. Thank you for reading and wish you a restful weekend.

Bris­tol My­ers Squibb sues No­var­tis for roy­al­ties sur­round­ing the use of trans­genic mice

Two Big Pharma companies are going to the mat over genetically modified mice in a licensing dispute.

Bristol Myers Squibb is suing Novartis in New York over a dispute concerning an evaluation, research and commercialization agreement stretching back to the late ’90s initially inked between Novartis and BMS’ predecessor Medarex. The deal in question allowed Novartis to use Medarex’s patented transgenic mice to develop therapeutic drugs. Novartis agreed to pay Medarex – and subsequently BMS – a royalty on sales of drugs it developed using the mice.